Posted on

New drug combination could extend life of cystic fibrosis patients

the-lungs-in-the-body

ground-breaking new form of treatment for cystic fibrosis could benefit nearly half of patients with the disease, a study has found.
An international research team has demonstrated that a combination of two different drugs targeting the most common genetic cause of cystic fibrosis helped to improve lung function and reduce the rate of pulmonary exacerbations.”These results represent a further major advance in finding treatments which correct the basic problem in cystic fibrosis and improve the lives of patients living with the condition,” reports Prof. Stuart Elborn, a co-author of the study from Queen’s University in Belfast, Northern Ireland.

Cystic fibrosis is a hereditary condition that causes cells producing mucus, sweat and digestive juices to secrete thicker and more sticky fluids than normal. These secretions often restrict and block ducts and tubes, particularly in the lungs and pancreas, severely inhibiting the lungs and digestive system.

The disorder is a life-threatening one. In the lungs, thick mucus reduces lung function and leads to chronic infection while in the pancreas the mucus prohibits enzymes from reaching the gut to enable the complete digestion of food.

Cystic fibrosis is caused by genetic mutations that fall into six different functional categories. The most common therapeutic target for the condition is the F508del mutation – almost half of patients with cystic fibrosis in the US have two copies of this mutation.

One drug, ivacaftor, is approved by the US Food and Drug Administration (FDA) for the treatment of a less common cystic fibrosis mutation, but had not previously been found effective in treating patients with two copies of the F508del mutation.

However, a phase 2 study indicated that combining ivacaftor with another drug called lumacaftor could be beneficial to patients with this mutation. As a result, the researchers conducted two phase 3 trials to evaluate how effective this drug combination would be.

Study findings represent ‘an exciting step forward’

A total of 1,108 patients with the most common form of cystic fibrosis participated in the randomized, double-blind, placebo-controlled study. Participants were aged 12 and above and were treated for 24 weeks in centers across the world.

The researchers found that treatment with the new drug combination led to a reduction in the number of hospital courses of antibiotic treatment required, alongside improvements in breathing test results, weight and quality of life.

Improvements in the nutritional status of the patients with cystic fibrosis were hypothesized by the researchers to reflect either better caloric absorption or a reduction in energy expenditure attributed to ameliorating the effects of lung disease.

“Just a few years ago, ivacaftor became the only FDA-approved drug for the genetic defect in cystic fibrosis, but it only works for genetic mutations found in a small portion of cystic fibrosis patients,” states study author Dr. Susanna McColley, professor of pediatrics at Northwestern University Feinberg School of Medicine, IL.

“Our study showed that combining ivacaftor with lumacaftor helps patients with the most common cystic fibrosis mutation. This is an exciting step forward.”

Dr. McColley says that more analyses and longer-term data are required for the team to ascertain whether this treatment can alter the course of cystic fibrosis and further extend the life expectancy of patients with the condition. At present, the median life expectancy for patients with the disease is 37 years.

Last week, the FDA Pulmonary-Allergy Drugs Advisory Committee met to consider the results of the study, published inNew England Journal of Medicine. Final approval from the committee is still pending.

Previously, Medical News Today reported on a study describing the role of “mini-lungs” in cystic fibrosis research. A team at the University of Cambridge in the UK has been able to successfully create organoid models in the laboratory as a new way to research and test new drugs.

 

Posted on

Is this the hangover treatment we have all been waiting for?

hangover new

Pedialyte’s ‘See The Lyte’ Campaign Reinvents Drink For Adult Use. Pedialyte’s new campaign uses popular drinking occasions, such as graduation season and St. Patrick’s Day, to promote its new product.

Pedialyte has made it clear that the upset stomach remedy you remember from childhood is all grown up. The product’s new “See the Lyte” campaign cleverly reflects its shift from nursing toddlers back from a bout of a stomach bug to nursing 20-somethings back from a weekend bender.

Vomiting, diarrhea, and general malaise are symptoms associated with both a stomach flu and a night of heavy drinking, so it would make sense that the recovery method would be similar. At least, that’s the idea an increasing number of young drinkers share. But what first began as an underground “quick fix” to the headache and grogginess caused by drinking too much soon became a nationwide trend. According to Abbott Laboratories, the creators of Pedialyte, sales have gone up nearly 60 percent since 2012, around a third of which came from adults.

“There’s an underground movement in social media to drive word of mouth,” explained Heather Mason, executive vice president at Abbott, as reported by National Monitor. “We saw increased use by adults.”

According to Mason, the drink’s new campaign is aimed to take advantage of the product’s potential for entering an adult market.

“We have high electrolyte and lower sugar content than common [hydration] beverages,” Mason said. “That combination caused us to say, ‘We need to be part of this.’”

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Posted on

Learn how to help a child who is choking.

first aid

1) Give up to five back blows. Hit them firmly on their back between the shoulder blades. If back blows do not dislodge the object, move on to step two.

2) Give up to five abdominal thrusts. Hold the child around the waist and pull upwards and inwards above their belly button. If abdominal thrusts do not dislodge the object, repeat steps one and two. Call 999 if the object has not dislodged after three cycles of back blows and abdominal thrusts.